Revalesio’s RNS60 program signals renewed momentum in adjunctive stroke therapeutics
Revalesio presents new RNS60 stroke data showing reduced brain tissue loss and shorter hospital stays. Discover what this could mean for stroke drug development.
Pharma & Biotech
Pharma & Biotech
Ananda Pharma’s ENDOCAN study explores whether pharmaceutical-grade CBD can address unmet needs in endometriosis care
Ananda Pharma launches Phase 2 ENDOCAN trial testing cannabidiol MRX1 for endometriosis pain. Explore what this study could change for women’s health.
Pharma & Biotech
AbbVie’s AFFIRM trial: what clinicians should watch next for risankizumab in Crohn’s disease
AbbVie reports positive Phase 3 AFFIRM trial results for risankizumab subcutaneous induction in Crohn’s disease. Discover what the findings mean for treatment.
Pharma & Biotech
How Glenmark Pharmaceuticals’ fluticasone inhaler approval could reshape the U.S. asthma inhaler market
Glenmark Pharmaceuticals wins FDA approval for generic fluticasone inhaler with 180-day exclusivity. Read what it means for the U.S. asthma drug market.
Medical Devices & Diagnostics
Can artificial intelligence predict delivery timing? Ultrasound AI’s FDA clearance tests the idea
Ultrasound AI wins FDA De Novo clearance for Delivery Date AI. Discover how predictive ultrasound analytics could change prenatal care and delivery timing.
Pharma & Biotech
Phase 3 CYPRESS miss forces Theravance Biopharma to rethink pipeline and accelerate strategic alternatives
Theravance Biopharma halted its ampreloxetine program after a Phase 3 failure. Discover what the CYPRESS results mean for the company and the neurogenic hypotension market.
Medical Devices & Diagnostics
What Innoblative’s SIRA CPT code approval signals for reimbursement, evidence generation, and surgical adoption
Innoblative’s SIRA device wins AMA Category III CPT code for intraoperative breast cancer ablation. Discover what this milestone means for surgery and reimbursement.
Pharma & Biotech
How XellSmart’s expanding IND portfolio is shaping the emerging market for CNS cell therapies
XellSmart’s iPSC-derived neuron therapy enters MSA-P trials after FDA and NMPA clearances. Discover what this means for regenerative neurology.
Pharma & Biotech
XtalPi and ReviR Therapeutics push AI-designed RTX-117 into human trials for rare neurological disorders
RTX-117 enters Phase 1 trials as an AI-designed therapy for Charcot-Marie-Tooth disease and VWM. Discover what this milestone means for rare disease drug discovery.
Medical Devices & Diagnostics
What the FDA IDE approval for ThermoSuit means for the future of neuroprotective stroke therapy
Life Recovery Systems begins pivotal ThermoSuit stroke trial to test rapid cooling therapy. Discover what this could mean for neuroprotection in ischemic stroke.